Risk Factors and Outcomes for COVID-19 in Autoimmune Inflammatory Diseases during the SARS-CoV-2 Pandemic: A...

Area of Science:

• Immunology
• Infectious Diseases
• Rheumatology

Background:

• Patients with autoimmune diseases (AID) face increased mortality risk from COVID-19 due to comorbidities and immunosuppressive therapies.
• Understanding the specific risks and outcomes for AID patients with COVID-19 is crucial for clinical management.

Purpose of the Study:

• To investigate and compare the risk factors and clinical outcomes of COVID-19 patients with and without autoimmune diseases (AID).
• To identify predictors of severe disease and mortality in the context of COVID-19 and AID.

Main Methods:

• A prospective cohort study design was employed, comparing 113 COVID-19 patients with AID to 113 matched controls.
• Data collected included clinical characteristics, biochemical markers, immunological treatments, and outcomes such as hospitalization duration, invasive mechanical ventilation (IMV), and mortality.

Main Results:

• Autoimmune disease patients exhibited lower levels of lactate dehydrogenase, C-reactive protein, and fibrinogen, along with reduced rates of IMV and lower in-hospital mortality compared to controls.
• Low oxygen saturation (SaO2 ≤ 88%) at hospitalization was a significant risk factor for IMV and in-hospital mortality.
• Anticoagulant therapy demonstrated a protective effect, associated with lower death rates in the AID group.

Conclusions:

• Patients with autoimmune diseases (AID) demonstrated more favorable outcomes when infected with COVID-19 compared to non-AID controls.
• Anticoagulation emerged as a key factor associated with reduced mortality among AID patients diagnosed with COVID-19.